Online inquiry

IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7340MR)

This product GTTS-WQ7340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VTCN1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001253849.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 79679
UniProt ID Q7Z7D3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7340MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11115MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ2743MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ2107MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ6808MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ6100MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7899MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ875MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ13576MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW